Roivant Sciences Ltd.
ROIV evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Market Cap:
- $29.63B
- Cash Runway:
- 44.2 mo
What it means
What to watch
Prepared research question
What matters most for ROIV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ROIV
Roivant Sciences Ltd. (ROIV) is a biopharmaceutical company focused on accelerating the development and commercialization of therapies across autoimmune, pulmonary, and other indications, with a pipeline including brepocitinib, IMVT-1402, and mosliciguat.
Key risk: No approved products yet
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Roivant Sciences Ltd..
Roivant Sciences Ltd. (ROIV) is a biopharmaceutical company focused on accelerating the development and commercialization of therapies across autoimmune, pulmonary, and other indications, with a pipeline including brepocitinib, IMVT-1402, and mosliciguat.
- Cash & equivalents of $1,248.5M as of 2026-06-30 [sec]
- Total revenue of $1.4M and net income of -$189.8M as of 2026-06-30 [sec]
- Shareholders' equity of $4,231.3M as of 2026-06-30 [sec]
- Brepocitinib NDA for dermatomyositis under FDA priority review with decision expected in 3Q 2026 [sec_mda · as of 2026-08-06]
- Positive Phase 2 results for mosliciguat in pulmonary hypertension associated with interstitial lung disease reported in September 2026 [news · published 2026-09-13]
What works
- Strong cash position of $1,248.5M as of 2026-06-30 provides runway for pipeline development and potential launches [sec]
- Multiple late-stage pipeline assets with near-term catalysts, including brepocitinib FDA decision and mosliciguat Phase 2 data [sec_mda · as of 2026-08-06]
- Immunovant financing of ~$550 million in December 2025 extends cash runway to potential launch of IMVT-1402 in Graves' disease [sec · filed 2026-07-29]
What to weigh
- Net loss of $189.8M as of 2026-06-30 with minimal revenue of $1.4M, indicating heavy reliance on external funding [sec]
- Expenses expected to increase substantially as the company funds clinical trials, manufacturing, and commercialization efforts [sec_mda · as of 2026-08-06]
- Operating results may fluctuate significantly quarter-to-quarter depending on trial timing and R&D expenditures [sec_mda · as of 2026-08-06]
From the filings
Quoted directly from source documents.
Brepocitinib NDA under FDA priority review for dermatomyositis
“FDA decision on brepocitinib in dermatomyositis | 3Q 2026”
SEC MD&A · August 6, 2026
Positive Phase 2 results for mosliciguat
“Roivant Sciences Ltd. (NASDAQ:ROIV) shares surged 18% on September 8 after the biotech company reported strong Phase 2 results for an experimental treatment for pulmonary hypertension.”
News · September 13, 2026
Catalyst timeline
- 2026-09-30 · FDA decision on brepocitinib in dermatomyositis — Priority review decision expected in 3Q 2026; approval would mark Roivant's first FDA-approved drug.
- 2026-12-31 · Topline data from Phase 2 trial of mosliciguat in PH-ILD — Data expected in 2H 2026; positive results could advance the pulmonary hypertension program.
- New mid/late-stage in-licensing announcements — Ongoing catalyst; Roivant plans to in-license multiple potentially category-leading drugs per year.
Risks & what to watch (3)›
Key risks
- No approved products yet — Roivant has minimal revenue ($1.4M) and relies on pipeline success; no FDA-approved drug as of mid-2026 [sec]
- Rising expenses — Expenses expected to increase substantially for clinical trials, manufacturing, and commercialization [sec_mda · as of 2026-08-06]
- Clinical trial uncertainty — Operating results may fluctuate significantly depending on trial timing and outcomes [sec_mda · as of 2026-08-06]
What to watch
- FDA decision on brepocitinib for dermatomyositis expected in 3Q 2026 [sec_mda · as of 2026-08-06]
- Topline data from Phase 2 trial of mosliciguat in PH-ILD expected in 2H 2026 [sec_mda · as of 2026-08-06]
- Potential launch of IMVT-1402 in Graves' disease, supported by Immunovant's extended cash runway [sec · filed 2026-07-29]
- Ongoing in-licensing announcements for mid/late-stage pipeline growth [sec_mda · as of 2026-08-06]
Sources: News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Roivant Sciences Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Roivant Sciences Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
44.2 months
D/E 0.09 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
No upcoming catalysts tracked
0 buys · 33 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
437
Total value held
$14.41B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 77,981,253 | $2.16B |
| morgan stanley | 51,828,325 | $1.44B |
| blackrock, inc. | 44,254,260 | $1.23B |
| qvt financial lp | 25,161,237 | $697.0M |
| ubs group ag | 22,619,472 | $626.6M |
| vanguard capital management llc | 20,680,572 | $572.9M |
| vanguard portfolio management llc | 19,838,698 | $549.5M |
| state street corp | 16,186,613 | $448.4M |
| adage capital partners gp, l.l.c. | 12,794,097 | $354.4M |
| goldman sachs group inc | 11,111,591 | $307.8M |
Showing top 10 of 437 institutional holders of Roivant Sciences Ltd.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 4.5%
- Days to cover
- 4.8
- Shares short
- 24,470,022
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ROIV short interestGovernance
Frequently asked questions
What is the AI investment thesis for Roivant Sciences Ltd.?
Roivant Sciences Ltd. (ROIV) is a biopharmaceutical company focused on accelerating the development and commercialization of therapies across autoimmune, pulmonary, and other indications, with a pipeline including brepocitinib, IMVT-1402, and mosliciguat.
What is Roivant Sciences Ltd.'s lead drug candidate?
Roivant Sciences Ltd.'s most advanced tracked candidate is imvt-1402 (Phase 2/Phase 3) for Difficult-to-Treat Rheumatoid Arthritis, Graves' Disease, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Sjögren's Disease, Cutaneous Lupus Erythematosus.
Who is the CEO of Roivant Sciences Ltd.?
Mr. Matthew Gline is the chief executive officer of Roivant Sciences Ltd. (ROIV).
Where is Roivant Sciences Ltd. headquartered?
Roivant Sciences Ltd. (ROIV) is headquartered in London, United Kingdom.
What therapeutic areas does Roivant Sciences Ltd. focus on?
Roivant Sciences Ltd. develops therapies across Neurology, Immunology, Cardiovascular, Respiratory, Dermatology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.